STSA · Satsuma Pharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $7.46M | - | $11.34M | $12.50M | $11.56M | - | $10.17M | $8.44M | $7.16M | - |
| SG&A | $3.31M | - | $4.07M | $3.90M | $3.99M | - | $3.16M | $3.38M | $3.29M | - |
| Total Operating Expenses | $10.77M | - | $15.41M | $16.40M | $15.55M | - | $13.33M | $11.83M | $10.45M | - |
| D&A | $0 | - | $100.0K | $100.0K | $92.0K | - | - | - | $80.0K | - |
| Operating Income | ($10.77M) | - | ($15.41M) | ($16.40M) | ($15.55M) | - | ($13.33M) | ($11.83M) | ($10.45M) | - |
| Interest Expense | - | - | - | $2.0K | $11.0K | - | $35.0K | $47.0K | $57.0K | - |
| Income Tax | $0 | - | - | - | $0 | - | - | - | $0 | - |
| Net Income | ($10.29M) | - | ($15.14M) | ($16.27M) | ($15.52M) | - | ($13.33M) | ($11.83M) | ($10.46M) | - |
| EPS - Basic | ($0.31) | - | ($0.48) | ($0.38) | - | - | - | - | - | - |
| EPS - Diluted | ($0.31) | - | ($0.48) | ($0.38) | - | - | - | - | - | - |
Balance Sheet
| Line item | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $19.53M | $16.43M | $40.56M | $23.76M | $21.36M | $15.84M | $42.26M | $53.86M | $102.22M | $36.33M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $874.0K | $1.91M | $1.94M | $1.63M | $1.80M | $1.47M | $1.65M | $3.11M | $1.14M | $3.38M |
| Current Assets | $43.38M | $54.81M | $67.56M | $72.47M | $84.08M | $99.85M | $109.96M | $126.23M | $136.41M | $73.79M |
| Total Assets | $43.48M | $54.94M | $75.04M | $80.15M | $93.67M | $109.83M | $122.30M | $135.32M | $144.06M | $81.03M |
| Current Liabilities | $5.83M | $8.12M | $6.66M | $7.89M | $6.58M | $8.49M | $6.62M | $7.58M | $5.35M | $8.05M |
| Long-term Debt | - | - | - | - | - | $833.0K | $1.33M | $1.83M | $2.33M | $2.83M |
| Total Liabilities | $5.83M | $8.12M | $6.66M | $7.96M | $6.69M | $8.49M | $6.62M | $7.58M | $5.91M | $9.10M |
| Stockholders' Equity | $37.65M | $46.82M | $68.38M | $72.19M | $86.98M | $101.34M | $115.67M | $127.74M | $138.15M | $71.94M |
| Retained Earnings | ($222.09M) | ($211.79M) | ($188.66M) | ($173.52M) | ($157.25M) | ($141.74M) | ($126.19M) | ($112.85M) | ($101.02M) | ($90.56M) |
Cash Flow
| Line item | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($11.38M) | - | - | - | ($14.32M) | - | - | - | ($8.48M) | - |
| Investing Cash Flow | $14.48M | - | - | - | $20.34M | - | - | - | ($344.0K) | - |
| Financing Cash Flow | - | - | - | - | ($500.0K) | - | - | - | $74.72M | - |
| CapEx | - | - | - | - | $24.0K | - | - | - | $1.27M | - |
| Free Cash Flow | - | - | - | - | ($14.34M) | - | - | - | ($9.76M) | - |
Ratios
| Metric | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | 0.92 | - | - | - | 0.93 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -23.7% | - | -20.2% | -20.3% | -16.6% | - | -10.9% | -8.7% | -7.3% | - |
| Return on equity | -27.3% | - | -22.1% | -22.5% | -17.8% | - | -11.5% | -9.3% | -7.6% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | -5.9% | - |
| Liquidity | ||||||||||
| Current ratio | 7.44 | 6.75 | 10.15 | 9.18 | 12.77 | 11.76 | 16.60 | 16.66 | 25.50 | 9.17 |
| Quick ratio | 7.44 | 6.75 | 10.15 | 9.18 | 12.77 | 11.76 | 16.60 | 16.66 | 25.50 | 9.17 |
| Cash ratio | 3.35 | 2.02 | 6.09 | 3.01 | 3.24 | 1.86 | 6.38 | 7.11 | 19.11 | 4.51 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | 0.01 | 0.01 | 0.01 | 0.02 | 0.04 |
| Debt / Assets | - | - | - | - | - | 0.01 | 0.01 | 0.01 | 0.02 | 0.03 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | -8200.0x | -1413.3x | - | -380.9x | -251.6x | -183.3x | - |
| Equity multiplier | 1.15 | 1.17 | 1.10 | 1.11 | 1.08 | 1.08 | 1.06 | 1.06 | 1.04 | 1.13 |
| Liabilities / Assets | 0.13 | 0.15 | 0.09 | 0.10 | 0.07 | 0.08 | 0.05 | 0.06 | 0.04 | 0.11 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 30.7% | - | -15.6% | -38.7% | -48.8% | - | -9.5% | -2.8% | 14.1% | - |
| Net income growth (YoY) | 33.7% | - | -13.6% | -37.5% | -48.4% | - | -10.7% | -5.0% | 11.2% | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | -46.9% | - | - | - | 26.6% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -56.7% | -53.8% | -40.9% | -43.5% | -37.0% | 40.9% | 39.4% | 36.0% | 32.8% | -37.6% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Satsuma Pharmaceuticals against the 5 most active filers in the same SIC group.